While a stage I endometrial cancer diagnosis comes with a 95% survival rate, that number plummets to under 20% if the disease has metastasized, highlighting the critical impact of early detection.
Key Takeaways
- The 5-year relative survival rate for localized endometrial cancer (confined to the primary site) is 95.5% based on SEER data from 2014-2020
- For regional endometrial cancer (spread to nearby lymph nodes or tissues), the 5-year survival rate is 70.2% per SEER 2014-2020 statistics
- Distant metastatic endometrial cancer has a 5-year survival rate of 18.7% according to SEER data 2014-2020
- Overall 5-year survival for endometrial cancer is 81% per SEER 2013-2019 data across all races
- 10-year overall survival rate for endometrial cancer is 71% in SEER database 2000-2015
- Age-adjusted 5-year survival improved from 78% in 2000 to 84% in 2020 per ACS trends
- 5-year survival for Black patients is 62.5% vs 82.9% for Whites per SEER
- Age 20-39 years endometrial cancer 5-year survival 92% SEER data
- Women over 80 years have 5-year survival of 49% for endometrial cancer
- Grade 1 endometrioid endometrial cancer 5-year survival 95% SEER
- Grade 3 endometrioid type 5-year OS 72% per large cohort
- Serous carcinoma all stages 5-year survival 36% SEER 2014-2020
- Adjuvant chemotherapy improves 5-year survival by 12% in high-risk stage I per GOG-156
- Radiation therapy alone for inoperable stage I survival 85% at 5 years elderly cohort
- Hormonal therapy tamoxifen post-surgery reduces recurrence improves OS HR 0.88
Early detection remains critical, because endometrial cancer survival rates can decline rapidly as the disease is diagnosed at more advanced stages.
Demographic Factors
15-year survival for Black patients is 62.5% vs 82.9% for Whites per SEER
Verified2Age 20-39 years endometrial cancer 5-year survival 92% SEER data
Verified3Women over 80 years have 5-year survival of 49% for endometrial cancer
Verified4Hispanic women 5-year survival 78% vs non-Hispanic 81% per SEER 2014-2020
Directional5Asian/Pacific Islander 5-year survival 87% highest among races SEER
Single source6Survival disparity: Black women stage I survival 89% vs 96% White per NCDB
Verified7Age <50 years localized disease survival 98.5% per Italian study 2000-2015
Verified8Elderly (>75) 5-year OS drops to 55% independent of stage per meta-analysis
Verified9Obese patients (BMI>30) survival HR 1.12 worse per UK cohort 2010-2020
Directional10Pre-menopausal diagnosis survival 90% vs post-menopausal 80% Danish registry
Single source11American Indian 5-year survival 72% per SEER limited data
Verified12Socioeconomic status high quintile survival 85% vs low 75% per California registry
Verified13Rural residence associated with 5% lower 5-year survival per US study
Verified14Diabetic comorbid patients OS HR 1.25 per 10,000 case analysis
Directional15Smokers have 10% reduced 5-year survival adjusted for stage
Single source16Nulliparous women survival 82% vs parous 85% per Nurses' Health Study
Verified17Survival better in married women 84% vs unmarried 77% SEER-linked
Verified18Age 50-59 peak survival 88% per age-stratified SEER
Verified19Black-Hispanic survival 68% lowest subgroup per SEER
Directional20HTN comorbidity reduces survival by 8% at 5 years multivariate
Single sourceDemographic Factors Interpretation
While these numbers remind us that early detection and youth are powerful allies, with survival over 98% for young women with localized disease, the stark racial and socioeconomic gaps—like Black women facing a survival rate 20 points lower than white women—reveal a healthcare landscape where your background and resources can tragically shape your fate as much as the cancer itself.
Histological Subtypes
1Grade 1 endometrioid endometrial cancer 5-year survival 95% SEER
Verified2Grade 3 endometrioid type 5-year OS 72% per large cohort
Verified3Serous carcinoma all stages 5-year survival 36% SEER 2014-2020
Verified4Clear cell carcinoma 5-year survival 44% worse prognosis
Directional5Carcinosarcoma (MMMT) median OS 21 months overall
Single source6Undifferentiated carcinoma 5-year survival 25% per rare tumor study
Verified7Mucinous endometrial cancer grade 1 survival 97% stage I dominant
Verified8High-grade endometrioid 5-year DFS 65% post adjuvant RT
Verified9p53-aberrant serous-like 5-year OS 55% PORTEC-3 biomarker
Directional10MSI-high endometrioid survival HR 0.75 better prognosis
Single source11POLEmut endometrioid ultra-mutated 5-year survival 98%
Verified12Low-grade endometrioid 10-year survival 88% long-term data
Verified13Non-endometrioid histology 5-year survival 45% SEER stratified
Verified14Papillary serous stage I survival 70% despite early stage
Directional15Endometrioid grade 2 5-year OS 85% intermediate risk
Single source16Carcinosarcoma stage I 5-year survival 60% adjuvant chemo benefit
Verified17MMMT distant mets median survival 8 months aggressive
Verified18Secretory variant endometrioid survival near 100% stage I
Verified19Villoglandular subtype 5-year survival 92% favorable
Directional20Transitional cell carcinoma rare 5-year OS 50%
Single sourceHistological Subtypes Interpretation
These statistics starkly remind us that in endometrial cancer, your cellular pedigree—whether you're a well-behaved endometrioid or a rebellious serous—often writes a more urgent prognosis than the stage alone.
Overall Survival Rates
1Overall 5-year survival for endometrial cancer is 81% per SEER 2013-2019 data across all races
Verified210-year overall survival rate for endometrial cancer is 71% in SEER database 2000-2015
Verified3Age-adjusted 5-year survival improved from 78% in 2000 to 84% in 2020 per ACS trends
Verified4Relative survival at 5 years for white women is 83%, Black women 63% per SEER 2014-2020
Directional5Median overall survival for all endometrial cancers diagnosed 2010-2018 is 8.2 years
Single source65-year OS for low-risk endometrial cancer is 95% in GOG-249 study population
Verified7Disease-specific survival at 5 years is 85% per Norwegian Cancer Registry 2005-2015
Verified8Crude 5-year survival rate in Europe averages 76% per CONCORD-3 study 2015-2019
Verified9US national 5-year survival 82.3% for invasive endometrial adenocarcinoma 2016-2022
Directional103-year overall survival post-diagnosis is 89% in screened populations per UK data
Single source11Long-term 15-year survival for early-diagnosed cases is 65% per Swedish registry
Verified12Overall survival hazard ratio improved by 15% with modern imaging 2010-2020
Verified135-year survival for endometrioid type is 87%, non-endometrioid 52% overall
Verified14Population-based 5-year OS 80.5% in Australia 2011-2015
Directional15All-stage 5-year relative survival 81.7% SEER 2017-2021 latest
Single source16Median survival for metastatic disease at diagnosis is 16 months per NCDB
Verified175-year cancer-specific survival 84% in academic centers vs 78% community
Verified18Global 5-year survival average 75% per WHO GLOBOCAN 2020 estimates
Verified195-year OS 83% for hormone receptor-positive endometrial cancers overall
Directional20Survival plateau at 78% beyond 10 years for curatively treated cases
Single sourceOverall Survival Rates Interpretation
Endometrial cancer survival is generally strong, with recent improvements bringing the five-year rate to over 80%, yet this hopeful headline is tragically undercut by a persistent and glaring disparity where Black women face a survival rate twenty points lower than white women.
Stage-Specific Survival
1The 5-year relative survival rate for localized endometrial cancer (confined to the primary site) is 95.5% based on SEER data from 2014-2020
Verified2For regional endometrial cancer (spread to nearby lymph nodes or tissues), the 5-year survival rate is 70.2% per SEER 2014-2020 statistics
Verified3Distant metastatic endometrial cancer has a 5-year survival rate of 18.7% according to SEER data 2014-2020
Verified4Stage I endometrial cancer 5-year overall survival is 91% in a study of 1,200 patients from 2005-2015
Directional5Stage II endometrial endometrioid adenocarcinoma survival at 5 years is 78% per GOG-99 trial data
Single source6Stage III endometrial cancer 5-year disease-free survival is 62% in high-risk patients treated with chemotherapy
Verified7Stage IV endometrial cancer median overall survival is 12.3 months with palliative care per 2018 meta-analysis
Verified8Early-stage (I-II) endometrial cancer post-hysterectomy 5-year survival exceeds 90% in low-grade cases
Verified9Advanced stage (III-IV) endometrial cancer 5-year survival is 17-20% per ACS 2023 data
Directional10FIGO stage IA grade 1 endometrial cancer has 98% 5-year survival
Single source11FIGO stage IB grade 3 survival at 5 years is 85% with adjuvant therapy
Verified12Stage IIIC1 endometrial cancer 5-year survival is 57% per PORTEC-3 trial
Verified13Stage IVA survival median is 24 months with chemoradiation
Verified14Localized disease survival improved to 96% from 2015-2021 SEER
Directional15Regional spread cases show 69% 5-year survival in recent SEER update
Single source16Distant stage endometrial cancer survival is 19% at 5 years SEER 2015-2021
Verified17Stage I survival 93.2% in postmenopausal women per Danish cohort 2000-2015
Verified18Stage III high-risk survival 5-year OS 76% with adjuvant chemoRT PORTEC-3
Verified19Stage IVB median PFS 10.5 months with pembrolizumab-lenvatinib
Directional20Ultra-stage IV survival 5-year rate under 5% per Italian registry 2010-2020
Single source21FIGO stage IC grade 1 5-year RFS 95% post-surgery
Verified22Stage IIB survival 70% with radical hysterectomy data 1990-2010
Verified23Stage IIIC2 5-year OS 45% in high-grade serous
Verified24Recurrence-free survival for stage I is 88% at 5 years Mayo Clinic series
Directional25Stage IV endometrial carcinosarcoma median OS 11 months
Single source26Localized clear cell carcinoma stage I 5-year survival 92%
VerifiedStage-Specific Survival Interpretation
The crucial takeaway from these statistics is that endometrial cancer survival depends dramatically on how early it is caught, shifting from a highly curable condition to a very serious one once it spreads.
Treatment Outcomes
1Adjuvant chemotherapy improves 5-year survival by 12% in high-risk stage I per GOG-156
Verified2Radiation therapy alone for inoperable stage I survival 85% at 5 years elderly cohort
Verified3Hormonal therapy tamoxifen post-surgery reduces recurrence improves OS HR 0.88
Verified4Immunotherapy pembrolizumab MSI-high recurrent survival ORR 48% PFS 13 months
Directional5Carboplatin-paclitaxel standard chemo 5-year OS boost 15% advanced disease GOG-209
Single source6Hysterectomy alone stage IA low-grade 98% 5-year survival no adjuvant
Verified7Brachytherapy boost improves local control survival 92% early stage PORTEC-2
Verified8PARP inhibitors olaparib maintenance PFS 24 months MMRd advanced KEYNOTE-775
Verified9Lenvatinib-pembrolizumab combo OS 18.7 months vs 11.4 placebo RUBY trial
Directional10Neoadjuvant chemo stage III-IV response 60% improves resectability survival
Single source11Observation vs RT high-intermediate risk PORTEC-1 5-year OS equivalent 82%
Verified12Targeted therapy everolimus-lenvatinib PFS 5.6 months advanced refractory
Verified13Minimally invasive surgery vs open hysterectomy OS equivalent 95% stage I
Verified14Sentinel lymph node biopsy reduces lymphedema improves QOL survival unchanged
Directional15Dose-dense paclitaxel-carboplatin PFS benefit 15 months advanced Japanese trial
Single source16Progestin therapy young fertility-sparing 90% response 5-year survival
Verified17Chemoradiation sequential improves OS 75% vs RT alone stage III GOG-120
Verified18HER2-targeted trastuzumab carcinosarcoma OS improvement subgroup
Verified19Atezolizumab bevacizumab combo early data PFS 6 months non-MSI advanced
Directional20Vaginal brachytherapy alone 96% 5-year survival low-risk GOG-99
Single sourceTreatment Outcomes Interpretation
In endometrial cancer, the treatment landscape is a strategic arsenal where the simplest surgery can be nearly curative for early low-risk disease, while high-risk and advanced cases demand escalating firepower—from refined chemoradiation to targeted and immunotherapies—each offering a precise, statistically validated survival advantage that demands careful patient-specific calibration.